Free Trial

Bone Biologics (BBLG) Competitors

Bone Biologics logo
$0.68 +0.01 (+0.76%)
As of 11:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BBLG vs. NURO, INBS, POAI, MHUA, IINN, TNON, DHAI, STRR, AEMD, and LYRA

Should you be buying Bone Biologics stock or one of its competitors? The main competitors of Bone Biologics include NeuroMetrix (NURO), Intelligent Bio Solutions (INBS), Predictive Oncology (POAI), Meihua International Medical Technologies (MHUA), Inspira Technologies Oxy B.H.N. (IINN), Tenon Medical (TNON), DIH Holding US (DHAI), Star Equity (STRR), Aethlon Medical (AEMD), and Lyra Therapeutics (LYRA). These companies are all part of the "medical equipment" industry.

Bone Biologics vs.

Bone Biologics (NASDAQ:BBLG) and NeuroMetrix (NASDAQ:NURO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Bone Biologics has a net margin of 0.00% compared to NeuroMetrix's net margin of -203.71%. NeuroMetrix's return on equity of -42.56% beat Bone Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bone BiologicsN/A -124.71% -111.64%
NeuroMetrix -203.71%-42.56%-39.26%

NeuroMetrix has higher revenue and earnings than Bone Biologics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bone BiologicsN/AN/A-$8.95MN/AN/A
NeuroMetrix$3.03M2.98-$6.53M-$4.59-0.96

In the previous week, NeuroMetrix had 2 more articles in the media than Bone Biologics. MarketBeat recorded 3 mentions for NeuroMetrix and 1 mentions for Bone Biologics. Bone Biologics' average media sentiment score of 1.87 beat NeuroMetrix's score of 0.29 indicating that Bone Biologics is being referred to more favorably in the media.

Company Overall Sentiment
Bone Biologics Very Positive
NeuroMetrix Neutral

Bone Biologics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, NeuroMetrix has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500.

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 19.4% of NeuroMetrix shares are owned by institutional investors. 7.5% of Bone Biologics shares are owned by company insiders. Comparatively, 7.3% of NeuroMetrix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NeuroMetrix received 284 more outperform votes than Bone Biologics when rated by MarketBeat users.

CompanyUnderperformOutperform
Bone BiologicsN/AN/A
NeuroMetrixOutperform Votes
284
56.46%
Underperform Votes
219
43.54%

Summary

NeuroMetrix beats Bone Biologics on 7 of the 11 factors compared between the two stocks.

Get Bone Biologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BBLG and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BBLG vs. The Competition

MetricBone BiologicsSurgical appliances & supplies IndustryMedical SectorNASDAQ Exchange
Market Cap$2.22M$9.17B$5.49B$7.97B
Dividend YieldN/A1.64%5.11%4.23%
P/E RatioN/A19.3322.6118.58
Price / SalesN/A70.97397.51103.15
Price / CashN/A19.6738.1834.62
Price / Book0.095.006.704.26
Net Income-$8.95M$284.66M$3.22B$248.31M
7 Day Performance-0.70%0.54%1.26%1.34%
1 Month Performance-18.80%2.82%3.73%3.92%
1 Year Performance-59.64%-16.46%15.82%5.33%

Bone Biologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BBLG
Bone Biologics
0.8979 of 5 stars
$0.68
+0.8%
N/A-56.9%$2.22MN/A0.002Positive News
NURO
NeuroMetrix
0.4065 of 5 stars
$4.32
-2.3%
N/A-0.2%$8.90M$3.03M-0.9420Analyst Forecast
News Coverage
Gap Up
INBS
Intelligent Bio Solutions
0.4076 of 5 stars
$1.21
+1.7%
N/A-52.4%$8.24M$3.03M0.0010Gap Up
POAI
Predictive Oncology
2.7948 of 5 stars
$0.87
-7.3%
$3.00
+245.8%
-23.1%$7.75M$1.62M-0.2830
MHUA
Meihua International Medical Technologies
0.7511 of 5 stars
$0.29
-7.1%
N/A-60.1%$7.20M$94.25M0.00620Gap Down
IINN
Inspira Technologies Oxy B.H.N.
0.5033 of 5 stars
$0.57
-3.3%
N/A-68.8%$7.15MN/A0.0020Short Interest ↑
TNON
Tenon Medical
2.7465 of 5 stars
$1.12
flat
$4.67
+316.7%
+54.6%$6.94M$3.28M-0.048
DHAI
DIH Holding US
1.2796 of 5 stars
$0.14
-4.4%
N/A-88.2%$6.82M$64.47M-0.48N/AShort Interest ↓
Gap Down
STRR
Star Equity
2.1237 of 5 stars
$1.80
-1.6%
N/A-52.5%$5.80M$53.36M-0.70460Short Interest ↓
Positive News
AEMD
Aethlon Medical
3.1574 of 5 stars
$0.33
-8.4%
$7.00
+2,029.0%
-72.8%$5.77M$570,000.00-0.2110Analyst Forecast
Short Interest ↓
News Coverage
LYRA
Lyra Therapeutics
2.9296 of 5 stars
$0.09
+0.9%
$1.25
+1,331.8%
-97.7%$5.75M$1.53M-0.0650Gap Up

Related Companies and Tools


This page (NASDAQ:BBLG) was last updated on 5/1/2025 by MarketBeat.com Staff
From Our Partners